On April 21, 2026, Assertio Holdings, Inc. announced that Garda Therapeutics, Inc. will initiate a tender offer to purchase all outstanding shares of Assertio’s common stock on April 29, 2026, related to their previously announced merger agreement dated April 8, 2026.